ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GENEVA, Switzerland August 3 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that Company Management will provide a corporate update at the Wedbush PacGrow Healthcare Conference to be held August 10-11, 2021 and the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021.

ObsEva to Present at Upcoming Investor Conferences

The stock price of Obseva SA (NASDAQ: OBSV) increased by over 42% during intraday trading. This is why it happened.

OBSV Stock Increases Over 42% Intraday: Why It Happened

Organon & Co

JERSEY CITY, N.J. & GENEVA, Switzerland--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), a global women's health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women's reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) recep

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?

Antares Pharma

GT Biopharma Inc

Ocugen, Inc.

Odonate Therapeutics

Palatin Technologies

Seelos Therapeutics

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

7 Penny Stocks For Your Watch List This Week If You Like Biotech In July

-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia –

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer -

ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting

Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of severe adenomyosis to be presented in an ePoster

ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting

PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation

ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021

- D ata from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous p reterm labor to be discussed in an oral presentation -

ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021

Geneva, Switzerland  and Boston, MA –  May 31 , 202 1  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that shareholders approved all Board proposals at its 2021 Annual General Meeting held on May 28, 2021.

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021

Geneva, Switzerland and Boston, MA –  May 25 , 202 1  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that its Board of Directors will propose the election at the 2021 Annual General Meeting of Shareholders to be held on May 28, 2021 of Anne VanLent as member of the Board of Directors for a term of one year expiring at the closing of the 2022 Annual General Meeting of Shareholders.

ObsEva Announces Proposed Changes to the Composition of its Board of Directors

Swiss biopharma ObsEva is on course to introduce an oral treatment for uterine fibroids, which affect 80% of women by menopause. The post OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today appeared first on InvestorPlace.

OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today

- PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post- treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment -

ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-

ObsEva Announces First Quarter 2021 Financial Results and Business Update

GENEVA, Switzerland and BOSTON, MA – May 6 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Clive Bertram as Chief Commercial Officer and member of ObsEva's Executive Committee, effective May 10, 2021. Wim Souverijns has served as Chief Commercial Officer of ObsEva since November 2018 and will leave the Company on June 30, 2021 to pursue a new opportunity. He will work to ensure a smooth transition with Clive Bertram.

ObsEva appoints Clive Bertram as Chief Commercial Officer

GENEVA, Switzerland and BOSTON, MA – May 4, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that it has completed enrollment for the Phase 3 EDELWEISS 3 trial of Yeslty® for patients with moderate to severe endometriosis-associated pain (EAP). Enrollment completion is an important milestone, and data from the primary endpoint readout are expected in Q4 2021.

ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain

GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the presentation of five e-Posters on linzagolix in the treatment of uterine fibroids at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), which will take place virtually from April 30 to May 2, 2021.

ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021

- Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 -

ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants

Geneva, Switzerland and Boston, MA –  April 22 , 202 1  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today published the invitation to its 2021 Annual General Meeting of Shareholders to be held on May 28, 2021 at 16:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.

ObsEva Annual General Meeting 2021

-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21-

ObsEva Announces Year End 2020 Financial Results and Business Update

Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference

Bellus Health Inc

Penny stocks like BLU stock and OBSV stock are gaining traction with retail investors, especially as analyst sentiment heats up. The post Penny Stocks News: Why Little-Known Plays OBSV and BLU Are Climbing Today appeared first on InvestorPlace.

Penny Stocks News: Why Little-Known Plays OBSV and BLU Are Climbing Today

Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that Company Management will be participating in a fireside chat and one-on-one investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference.

ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Geneva, Switzerland and Boston, MA – Thursday 11 February, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced today that its board of directors approved on February 10, 2021 an increase of its share capital from 69,629,347 to 81,220,471 through the issue of 11,591,124 new registered shares at an issue price of 1/13 of a Swiss Franc each, after registration of 3,406,480 new shares issued out of the company's conditional share capital. The 11,591,124 new shares, to be issued out of the company's authorized capital, will be fully subscribed for by ObsEva USA Inc., its 100% wholly owned subsidiary, and listed on the SIX Swiss Exchange on or around February 18, 2021. The transaction has been decided to provide the group with additional treasury shares that can be used in the future to raise funds in an efficient manner, as well as for the equity plans of the company and its subsidiaries.

News for ObsEva Stock (OBSV)